Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521794 · ClinicalTrials.gov registry record
Characteristics of Andersen-Tawil Syndrome
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 28
- Enrollment target
NCT00521794: Completed study, sponsored by University of Rochester.
NCT00521794 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00521794 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
Andersen-Tawil Syndrome (ATS) is a rare, genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and developmental abnormalities. Disease symptoms can vary, the cause of some ATS cases remains unknown, and no specific treatment has been identified. The purpose of this multi-site study is to better characterize ATS, establish whether symptoms change over time, and determine if symptoms are related to a mutation in the KCNJ2 gene.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-11 |
| Est. Completion | 2012-10 |
What the finished NCT00521794 record still lists
NCT00521794 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00521794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00521794 about?
NCT00521794 is a clinical study titled "Characteristics of Andersen-Tawil Syndrome". Andersen-Tawil Syndrome (ATS) is a rare, genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and developmental abnormalities. Disease symptoms can vary, the cause of some ATS cases remains unknown, and no specific treatment has been identif...
What is the current status of trial NCT00521794?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2007-11. Estimated completion is 2012-10.
Who is sponsoring clinical trial NCT00521794?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia